Table 4.
Secondary efficacy outcome assessments during the 13 weeks after the initiation of treatment with each product, linear mixed model—mITT population
| Covariate: product | Least square means: estimate [95% CI] | Differences: estimate [95% CI] | P value |
|---|---|---|---|
| MMRC new 10‐sum score | |||
| IqYmune® | 88.8 [87.2, 90.4] | 0.15 [−0.56, 0.85] | 0.67 |
| Kiovig® | 88.7 [87.3, 90.1] | ||
| Rasch‐built MMRC 10‐sum score | |||
| IqYmune® | 55.9 [55.3, 56.4] | 0.12 [−0.22, 0.46] | 0.46 |
| Kiovig® | 55.7 [55.2, 56.3] | ||
| MMRC 14‐sum score | |||
| IqYmune® | 127.6 [125.6, 129.7] | 0.10 [−0.65, 0.85] | 0.79 |
| Kiovig® | 127.5 [125.8, 129.3] | ||
| Total INCAT disability score | |||
| IqYmune® | 2.5 [2.21, 2.74] | −0.03 [−0.29, 0.23] | 0.7974 |
| Kiovig® | 2.5 [2.32, 2.71] | ||
| Normalised grip strength (%) | |||
| IqYmune® | 52.3 [47.0, 57.7] | −1.53 [−5.80, 2.73] | 0.46 |
| Kiovig® | 53.9 [49.4, 58.3] | ||
Abbreviations: CI, confidence interval
Modified Medical Research Council (MMRC) new 10‐sum score (range 0‐100), Rasch‐built MMRC 10‐sum score (range 0‐60), MMRC 14‐sum score (range 0‐140), a higher value indicates better muscle strength; Total INCAT disability score (range 0‐10), a higher value indicates maximal disability. Modified‐intent‐to‐treat population (mITT, N = 22).